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Background: Our objective was to develop a prognostic stratification tool that enables patients with cancer and pulmonary embolism (PE),
whether incidental or symptomatic, to be classified according to the risk of serious complications within 15 days.
Methods: The sample comprised cases from a national registry of pulmonary thromboembolism in patients with cancer (1075 patients from 14
Spanish centres). Diagnosis was incidental in 53.5% of the events in this registry. The Exhaustive CHAID analysis was applied with 10-fold cross-
validation to predict development of serious complications following PE diagnosis.
Results: About 208 patients (19.3%, 95% confidence interval (CI), 17.1–21.8%) developed a serious complication after PE diagnosis. The 15-day
mortality rate was 10.1%, (95% CI, 8.4–12.1%). The decision tree detected six explanatory covariates: Hestia-like clinical decision rule (any risk criterion
present vs none), Eastern Cooperative Group performance scale (ECOG-PS; o2 vs X2), O2 saturation (o90 vs X90%), presence of PE-specific
symptoms, tumour response (progression, unknown, or not evaluated vs others), and primary tumour resection. Three risk classes were created (low,
intermediate, and high risk). The risk of serious complications within 15 days increases according to the group: 1.6, 9.4, 30.6%; Po0.0001. Fifteen-day
mortality rates also rise progressively in low-, intermediate-, and high-risk patients: 0.3, 6.1, and 17.1%; Po0.0001. The cross-validated risk estimate is
0.191 (s.e.¼ 0.012). The optimism-corrected area under the receiver operating characteristic curve is 0.779 (95% CI, 0.717–0.840).
Conclusions: We have developed and internally validated a prognostic index to predict serious complications with the potential to impact
decision-making in patients with cancer and PE.
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Pulmonary embolism (PE) is one of the most common and feared
complications in cancer patients, given its frequency and the
suffering it entails (Sørensen et al, 2000). There is a 15–30%
prevalence rate of PE in necroscopic series for the most
thrombogenic tumours, owing to interactions between the
mechanisms of tumorigenesis, haemostatic activation, and other
factors (Svendsen and Karwinski, 1989). The introduction of
multidetector computed tomography (CT) has increased detection
rates of incidental PE, present in 2–8% of the studies performed in
cancer patients (Dentali et al, 2010). In some recent series,
incidentally diagnosed PE accounted for aB50% of embolic events
(Font et al, 2014, 2016). On the other end of the spectrum of
severity, PE is also a common cause of fatal events in daily practice,
as well as in trials with new targeted therapies (Ranpura et al, 2011;
Den Exter et al, 2013).
Classifying prognosis in PE is important, in as much as episodes
classified as low risk might be eligible for support reductions (e.g.,
outpatient management or early discharge, etc.), thereby lowering
costs and enhancing patient comfort without compromising safety.
In contrast, subjects at higher risk should receive stepped up care
or monitoring (Streiff et al, 2013). Different studies have identified
several prognostic factors for cancer-associated symptomatic PE,
most decisive among them being the presence of metastasis,
immobilisation, low weight, or altered vital signs (Kline et al, 2012;
Den Exter et al, 2013; Font et al, 2014, 2016). Several prospective,
cohort studies have based selection of low-risk patients eligible for
outpatient treatment on pragmatic clinical decision rules (CDR),
such as the HESTIA study eligibility criteria, which are based
prominently on altered vital signs and risk of bleeding (Siragusa
et al, 2005; Zondag et al, 2011; Font et al, 2014; Weeda et al, 2016).
On the other hand, prognostic multivariate models have been
created, such as the RIETE registry scale and POMPE-C score, that
predict 30-day mortality probability following PE (Kline et al,
2012; Den Exter et al, 2013); although, at best, they are marginally
superior to other classifications developed for PE in the general
population (e.g., PESI or sPESI; Carmona-Bayonas et al, 2016).
Nevertheless, using any of them to assist in decision-making
involves problems, not least of which is that their suitability for
incidental PE has yet to be proven (Kline et al, 2012; Den Exter
et al, 2013). Furthermore, they are not sensitive to competitive
risks, such as increased bleeding, responsible for some 10% of early
mortality, or cancer progression, which accounts for 50% of 30-day
mortality after a PE event (Den Exter et al, 2013; Carmona-
Bayonas et al, 2016).
Consequently, there is no adequate prognostic stratification
method for incidental and symptomatic PE. In this study, we have
attempted to refine the classification of the entire spectrum of
cancer-associated PE by combining an adaptation of the HESTIA
criteria with other explanatory covariates and modelling a decision
tree procedure.
MATERIALS AND METHODS
Patients. The source of information is an observational registry of
consecutive cases of cancer-associated PE, who received care at 14
Spanish hospitals between 2004 and 2015 (Registro de Embolia
Pulmonar en Pacientes con Neoplasias, EPIPHANY registry for its
Spanish acronym). This registry’s design, methods, and character-
istics have been previously reported in depth (Carmona-Bayonas
et al, 2016; Font et al, 2016; Plasencia-Martı́nez et al, 2016). Briefly
put, the basic eligibility criteria required that patients be adults
(X18 years) with a PE diagnosis confirmed by means of objective
imaging (CT angiography scans, high probability scintigraphy, or
CT scheduled to assess tumour response or for other reasons). In
order to choose a truly oncological population, subjects were
withdrawn from the study if the PE had occurred more than 1
month prior to the diagnosis of cancer, or if more than 1 month
had elapsed since completing adjuvant chemotherapy. Patients
were also excluded if they had not received anticoagulant therapy
without justification according to international clinical practice
guidelines (Streiff et al, 2013).
Given that the study included a prospective observation
component until closure, in case of multiple events, only one
was considered to be the index PE, defined as the evaluable PE
closest to the time of recruitment. The remaining PEs in the same
patient were considered ‘previous history’ if they took place prior
to the index PE, or ‘recurrence’, if subsequent to it. The registry
was approved by the local Ethics Committees at each centre;
informed consent was obtained from all living participants.
Study design. The main objective of this study was to develop a
prognostic model, the EPHIPANY index, for cancer patients and
both incidental, as well as symptomatic PE. Given that it was a
non-intervention database, the data reflect genuine clinical profiles
and the decisions physicians make in line with their clinical
practice. The data were collected from medical records or directly
from the patients, together with clinicians with experience in
cancer support treatment and radiologists who are subspecialised
in diseases of the chest. All the investigators were trained in the
study protocol requirements and the data were monitored in situ
or by phone. The data were gathered by means of an electronic
capture system, designed to refine inconsistencies and resolve data
errors in real time. Data acquisition was not blinded. The
minimum observation period was 3 months from the time PE
was diagnosed, although longer follow-up was required whenever
possible. The variables were collected during routine or unsched-
uled medical appointments.
Variables. The main outcome measure in this study was the
occurrence of a serious medical condition between PE diagnosis on
imaging and 15 days later. Serious complications are events that
lead to serious clinical deterioration or death; for example, systolic
blood pressure o90 mm Hg, acute respiratory failure, right-side
heart failure, acute kidney failure, major bleeding, or any other
event the investigator deems serious (Supplementary Table 1).
Other secondary end points were all-cause 30-day mortality, the
cause of 30-day mortality, and 30-day venous or arterial
rethrombosis. ‘Rethrombosis’ was defined as a second thrombotic
event after appropriate PE treatment or progression of a previous
venous thromboembolism (VTE) despite proper anticoagulant
therapy. Rethrombosis was not considered to be a serious
complication in the absence of the afore-named criteria. An
autopsic diagnosis notwithstanding, researchers attributed the
cause of death on the basis of a clinical history review and
findings from complementary testing. Demise was deemed to be
due exclusively to PE when there was a direct causal relationship
through a concatenation of events associated to the thrombosis
pathophysiology. ‘Mixed’ deaths were defined by the presence of a
temporal relationship between patient demise and PE, although
other intercurrent complications (e.g., infection or tumour
progression) might plausibly play a relevant role. Death was
considered unrelated to PE if there was no temporal relationship or
concatenation of clear events. ‘Multiple’ was accepted as a response
when there was a resumption of overlapping causes.
The potential explanatory covariates were selected after a
bibliographic review and consultation with experts, taking into
account their availability at patients’ bedside. Data recording did
not allow for lost data for outcomes, survival times, and basic
demographic and clinical characteristics (vital signs, tumour status,
performance status, etc.).
The ‘CDR variable’ was defined as adaptation of Hestia’s study
eligibility criteria used in previous studies (Zondag et al, 2011;
Weeda et al, 2016). These criteria are typified by the presence of at
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least one of the following: systolic blood pressure o100 mm Hg,
arterial oxygen saturation o90%, respiratory rate X30 breaths per
minute, pulse X110 beats per minute, sudden or progressive
dyspnoea, other serious complications, constituting admission
criteria in and of themselves, and clinically relevant bleeding, high
risk of bleeding, or platelets o50 000 mm 3. The CDR was assessed
immediately prior to the time of radiological diagnosis of PE.
Other explanatory covariates included: age, gender, tumour
stage, type of cancer, use of targeted cancer therapies, tumour
response at the time of PE based on radiological criteria, Response
Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenhauer
et al, 2009), Eastern Cooperative Group Performance Status scale
(ECOG-PS; Oken et al, 1982), chronic obstructive pulmonary
disease, prior cardiovascular disease, chronic kidney failure,
concurrent deep vein thrombosis or a history of VTE, development
of PE during treatment for a previous VTE, troponin levels
(normal or high), creatinine clearance (normal, low), incidental or
symptomatic diagnosis of the PE, presence of PE-specific
symptoms, right ventricular diameter, additional radiological
findings, Qanadli index (Qanadli et al, 2001), interventricular
septal anomalies, presence of a single or multiple PE, oxygen
saturation, blood pressure, heart and respiratory rates, previous
tumour bleeding, prior use of antiaggregants, and major surgery in
the previous month. Standardised definitions were used for each
variable (Supplementary Table 1).
Development of a decision tree model. Classifications based on
decision tree modelling seek to discover how the outcome variable
is linked to the potential explanatory factors and, specifically, the
configuration of these factors. This method is considered
appropriate as the contribution of the explanatory covariates
cannot be assumed to be necessarily additive or linear (Yohannes
and Hoddinott, 1999; Lewis, 2000). The Exhaustive CHAID
algorithm builds a decision tree by means of repeated partitions
of each subset into two or more child nodes, beginning with the full
database (Biggs et al, 1991). This methodology was used to
determine the strength of association between the presence of
serious complications within 15 days and the previously mentioned
potential predictors. To determine the best split in each node, the
categories of each predictor were merged into pairs until
statistically significant differences were no longer observed within
each component of the pair in comparison to the target variable.
The predictors that produced the most significant partitions were
then recursively chosen. Thus, the algorithm identified the main
interactions and built subgroups defined by the different sets of
independent variables. The level of significance for splitting nodes
(asplit) was 0.05. The Bonferroni method was used to adjust the
value of significance.
To cope with the overfitting and instability inherent to the
decision tree, a 10-fold cross-validation procedure was applied.
Thus, the data were randomly divided into 10 equal subsets. Trees
were systematically built in 9 of those partitions (training subsets)
and then tested in the remaining group (testing subset). Cross-
validation produces a single, final model. ‘Risk’ is defined as the
proportion of cases incorrectly classified by each of the individual
trees; whereas the cross-validated risk estimate is the average of the
risks of all the trees. This analysis was performed with the SPSS
23.0 software (SPSS Inc., Chicago, IL, USA). The bootstrap (1000
replications) optimism-corrected area under the receiver operating
characteristic curve (ROC) was estimated using R software with the
rms package (Harrell et al, 2015).
Finally, the percentage of serious complications was calculated
in each of the terminal nodes of the tree and this was used to create
the EPHIPANY rule, a simplified classification based on three
categories: low, intermediate, and high risk. The predictive value of
this classification was estimated by means of the odds ratio (OR)
and its 95% confidence interval (95% CI) between the groups
thereby generated and the appearance of the study end point.
Cumulative hazards curves were calculated to establish the changes
in hazard over time for each prognostic category.
RESULTS
Patient characteristics. Patient characteristics are summarised in
Table 1. Pulmonary embolism was incidentally diagnosed in 53%
of the cases. Twenty-eight percent (n¼ 302) of the episodes were





Mean (s.d.) 64 (12)
Males 492 (45.8%)
Active smokers 147 (13.7%)
COPD 128 (11.9%)










TNM tumour stage IV at the time of PE 791 (73.6%)




Progressive disease/unknown/not evaluated 647 (60.2%)
Previous VTE 126 (11.7%)
Therapy in the previous month
Major surgery 79 (7.3%)
Chemotherapy 576 (53.6%)
Targeted therapy 142 (13.2%)
Hormone therapy 90 (8.4%)
ESA 52 (4.8%)
Antiplatelet therapy 100 (9.3%)
Location of treatment
Hospital admission 692 (64.4%)
Intensive care unit 33 (3.1%)
Home therapy 294 (27.4%)
Early discharge (o72 h) 47 (4.4%)
Home hospitalisation 8 (0.7%)
Initial therapy with LMWH 991 (92.2%)
Clinical findings
Heart rate 4110 beats per minute 231 (21.5%)
Systolic pressure o100 mm Hg 109 (10.1%)
Respiratory rate X30 times per minute 80 (7.4%)
Body temperature o36 1C 24 (2.2%)
Altered mental status 29 (2.7%)
Arterial oxygen saturation value o90% 166 (15.4%)
Incidental PE diagnosis 564 (53.5%)
PE-specific symptoms 517 (48.1%)
Surgery of primary tumour 473 (44.0%)
Abbreviations: COPD¼ chronic obstructive pulmonary disease; ECOG-PS¼Eastern Coop-
erative Oncology Group Performance status scale; ESA¼ erythropoiesis-stimulating agent;
LMWH¼ low-molecular weight heparin; PE¼pulmonary embolism; TNM¼ tumour node
metastasis; VTE¼ venous thromboembolism. The data entries represent percentages
calculated with respect to columns, with the exception of age. P-values were calculated with
the Linear-by-Linear association test, except for the continuous variable ‘age’ for which the
Kruskal–Wallis test was used. Risk categories are defined according to the end nodes of the
decision tree in Figure 2.
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treated at home. All patients received anticoagulation (initial
therapy with low-molecular weight heparin in 92%). At the time of
PE diagnosis, 73.6% of the patients had a metastatic tumour and
53.6% were receiving chemotherapy. The most common tumours
were breast, lung, and colon cancer, accounting for 54.7% of the
series. The recruitment process is illustrated in Figure 1.
Outcomes. The main end point of this study, serious complications
within 15 days, occurred in 208 patients (19.3%; 95% CI, 17.1–21.8%).
The 15-day mortality rate was 10.1% (95% CI, 8.4–12.1) and of the
109 patients who died within that period, 45 (41%) did so as a result
of tumour progression and not PE (Table 2). The rates of embolic
recurrence and major bleeding were 4% and 2%, respectively.
Decision tree. Figure 2 shows the decision tree model with the
15-day, serious complications data for each end node. The
Exhaustive CHAID method selected six explanatory covariates
from the initial 39: the Hestia-like CDR variable (any risk factor
present vs none), ECOG-PS (o2 vs X2), oxygen saturation
(o90 vs X90%), presence of PE-specific symptoms, previous
tumour response evaluation (tumour progression, unknown, or not
evaluated vs others), and prior surgical resection of primary
tumour. While other additional nodes involving more variables
could be generated, they did not provide any incremental risk
discrimination.
The best predictor in the root node was the Hestia-like CDR
variable; the episodes that did not meet any of these criteria had a
lower risk of serious complications within 15 days, in comparison
with episodes that satisfied at least one of them (4.7 vs 29.7%; OR
0.11, 95% CI, 0.07–0.18; Po0.0001) and 15-day mortality (2.5 vs
15.6%; OR 0.13; 95% CI, 0.07–0.25; Po0.0001), respectively. The
decision tree makes it possible to elaborate on the prognostic
stratification in seven terminal nodes. For purposes of practicality,
they are summarised into three risk categories: high, intermediate,
and low. Supplementary Table 2 outlines the demographic and
clinical characteristics of each subgroup.
Low risk encompasses patients without any Hestia-like CDR
criteria, and with controlled tumours or resected primary tumours,
with a risk of serious complications of between 1.4–3.4% and 0.3%
15-day mortality. Tumours with any of the CDR risk factors were
at high risk (complications rate, 20–55%), with the exception of the
group consisting of patients with a good performance status, and
no PE-specific symptoms, who had an intermediate level of risk.
This risk group would also include all stable patients having
uncontrolled or unevaluated tumours, and without surgery for the
primary tumour, with a 10.6% risk of complications. The cross-




CT scan quality did not allow PE assessment
(n=5)
Declined to participate (n=6)
Missing values (n=16)




Figure 1. Study flow diagram. CT, computed tomography; PE, pulmonary embolism.
Table 2. Main outcomes
Outcome
Overall data set
n¼1075 %, (95% CI)
15-day serious complicationsa
Overall 208 19.3%, (17.1–21.8)
Systolic BP o90 mm Hg 50 4.7%, (3.5–6.1)
Acute respiratory failure 86 8.0%, (6.4–9.8)
Fibrinolysis 7 0.7%, (0.2–1.4)
Major bleeding 54 5.0%, (3.8–6.5)
Acute right ventricular failure 22 2.0%, (1.3–3.1)
Acute renal failure 17 1.6%, (0.9–2.5)
Admission to ICU 21 2.0%, (1.2–3.0)
Cardiopulmonary resuscitation 4 0.4%, (0.1–0.9)
Non-invasive ventilation 9 0.8%, (0.4–1.6)
Oro-tracheal intubation 4 0.4%, (0.1–1.0)
Death 109 10.1%, (8.4–12.1)
Other 42 3.9%, (2.8–5.3)
Causes of 15-day mortality
Death caused exclusively by PE 19 1.8%, (1.1–2.8)
PE-related death, mixed 17 1.6%, (0.9–2.5)
Fatal bleeding 6 0.6%, (0.2–1.2)
Cancer 45 4.2%, (3.1–5.6)
Infection 8 0.7%, (0.3–1.5)
Arterial thrombosis 0 0
Other/unknown 14 1.3%, (0.7–2.2)
15-day venous rethrombosis 8 0.7%, (0.3–1.5)
All-cause 30-day mortality 153 14.2%, (12.2–16.5)
30-day serious bleeding 59 5.5%, (4.2–7.0)
30-day venous rethrombosis 12 1.1%, (0.6–2.0)
Abbreviations: BP¼blood pressure; CI¼ confidence interval; ICU¼ intensive care unit;
PE¼pulmonary embolism.
aThese events are not mutually exclusive.
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corrected value of the area under the ROC curve is 0.779 (95% CI,
0.717–0.840).
Outcomes according to risk groups are reported in Table 3. The
risk of serious complications within 15 days increases with the
group: 1.6, 9.4, 30.6%; Po0.0001. The risk of 15-day mortality also
raises progressively, in patients of low, intermediate, and high risk:
0.3, 6.1, and 17.1%; Po0.0001. It is worth noting that high–
intermediate-risk patients had increased risk of complications, with
OR of 17.2 (95% CI, 7.7–40.3), Po0.0001, and death OR of 49.5
(95% CI, 6.8–356.9), Po0.0001.
Figure 3 illustrates the cumulative hazard function. Events are
seen to be evenly distributed throughout the 15 days and do not
cluster in the first hours following diagnosis of PE. The log-rank
test reveals that the survival functions factored by prognostic
categories are significantly different (Po0.0001).
DISCUSSION
This study reports on the development of a decision tree model to
stratify any cancer patient with PE according to the risk of serious
complications within 15 days. Unlike other prognostic tools, the
EPIPHANY index is applicable across the entire spectrum of PE
severity, including both incidental and symptomatic events (Wicki
et al, 2000; Aujesky et al, 2006; Uresandi et al, 2007; Jiménez et al,
2010; Kline et al, 2012; Den Exter et al, 2013). The model is a
validation and extension of the CDR proposed in several
clinical trials with the aim of pragmatically selecting low-risk
patients eligible for outpatient care (Siragusa et al, 2005; Zondag
et al, 2011; Font et al, 2014; Weeda et al, 2016). These decision-
making rules are based on the combination of altered vital
signs (e.g., hypotension, hypoxaemia, tachycardia, etc.) and factors
that point toward a high risk of bleeding or other contraindications
to receiving treatment in the home. Moreover, the EPIPHANY
rule incorporates another five covariates that include discrimina-
tory characteristics typical in cancer patients that are easily
accessible at patients’ bedside, such as ECOG-PS, evaluation
of tumour response prior to PE using RECIST 1.1 criteria,
previous primary tumour resection, oxygen saturation, and the
presence or absence of PE-specific symptoms. All these variables
have been widely used in various contexts to predict clinical
outcome and there is good reason to think that they are




Node 7 Node 8 Node 9 Node 10
NoYesSaO2≥90%SaO2<90% YesNo
Node 11 Node 12
Node 4 Node 5 Node 6
Node 2





At least one risk factor present
≥2 <2
ECOG performance status scale
Pulse oximetry PE-specific symptoms Surgery of the primary tumour
Tumour response assessment at the time of PE
Progressive disease/
unknown/ not evaluated
Complete or partial response/stable
disease / no evidence of disease
No risk factor present
Adj.P-value=0.000, Chi-square=104.696,df=1
Adj. P-value=0.000, Chi-square=38.920,df=1
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Figure 2. EPIPHANY Index for the prediction of serious complications. The bars show the percentage of patients with no complications (light
gray) or with complications (dark gray) within each node. The ‘Clinical Decision Rule’ variable encompasses the following characteristics: (1) systolic
blood pressure o100 mm Hg, (2) arterial oxygen saturation o90%, (3) respiratory rate X30 breaths per minute, (4) pulse X110 beats per minute,
(5) sudden or progressive dyspnoea, and (6) clinically relevant haemorrhage, high risk of bleeding, or platelets o50 000 mm 3. The patient is
classified as low or high risk according to whether they exhibit none of these characteristics or at least one of them. CDR, clinical decision rule;
ECOG-PS, Eastern Cooperative Group Performance Status scale; PE, pulmonary embolism; SaO2, arterial oxygen saturation.
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Uresandi et al, 2007; Jiménez et al, 2010; Kline et al, 2012; Den
Exter et al, 2013).
The ECOG-PS has been largely acknowledged in oncology to
predict toxicity and adverse clinical outcomes in various contexts
(Oken et al, 1982). In general, functional worsening points to
severe underlying pathology, poorer physiological reserve, and
decreased mobility, thereby making patients more prone to
thrombotic risk (Jiménez et al, 2010; Den Exter et al, 2013).
Patients having any risk factor and poor functional status have a
worse prognosis than those with a good functional status,
particularly when PE diagnosis is incidental. On the other hand,
we have detected a new variable that should be incorporated into
the CDR: evaluation of tumour response prior to PE based on
RECIST radiological criteria, which determines short-term prog-
nosis following PE. Tumours in progression or those at risk for
progression because response could not be assessed are at higher
risk for complications than those with controlled disease or with
no evidence of disease, even in the absence of other prognostic
factors. In fact, resection of the primary tumour appears to be the
only thing that protects individuals with tumours in progression
and no other risk factor facing a complicated clinical course. This
variable likely improves prognosis as a consequence of decreasing
local complications, such as serious bleeding (Lee et al, 2009). In
fact, in this series, bleeding was located in the primary tumour in
43% of the cases, which rose to 50% in subjects who died due to
haemorrhage.
Remarkably, some patients diagnosed incidentally displayed
PE-specific symptoms upon meticulous anamnesis, as reported
by other authors (O’Connell et al, 2006). Therefore, the absence
of PE-specific symptoms does not correspond exactly with
incidental PE.
The decision tree model classification method used after the
Exhaustive CHAID procedure is one of the differences that
distinguish the EPIPHANY index from other models (Wicki et al,
2000; Aujesky et al, 2006; Uresandi et al, 2007; Jiménez et al, 2010;
Kline et al, 2012; Den Exter et al, 2013). This design was chosen
given the interest in generating a classification that would
reasonably imitate authentic decision-making. This means that,
unlike a binary logistic regression, which postulates the existence of
additive effects that contribute to explaining outcome, decision
trees factor in the existence of strong interactions between variables











nodes 7, 8, 9
n¼557 P-value
15-day complications
Overall 208 (19.3%) 6 (2.0%) 20 (9.4%) 182 (32.7%) o0.0001
Hypotension 50 (4.7%) 0 0 50 (9.0%) o0.0001
Acute respiratory failure 86 (8.0%) 1 (0.3%) 1 (0.5%) 84 (15.1%) o0.0001
Fibrinolysis 7 (0.7%) 0 0 7 (1.3%) 0.019
Major bleeding 54 (5.0%) 3 (1.0%) 5 (2.3%) 46 (8.3%) o0.0001
Right-side heart failure 22 (2.0%) 0 2 (0.9%) 20 (3.6%) o0.0001
Acute kidney failure 17 (1.6%) 0 1 (0.5%) 16 (2.9%) 0.001
ICU admission 21 (2.0%) 0 0 21 (3.8%) o0.0001
Cardiopulmonary resuscitation 4 (0.4%) 0 0 4 (0.7%) 0.075
Non-invasive mechanical ventilation 9 (0.8%) 0 0 9 (1.6%) 0.008
Oro-tracheal intubation 4 (0.4%) 0 0 4 (0.7%) 0.076
Demise 109 (10.1%) 1 (0.3%) 13 (6.1%) 95 (17.1%) o0.0001
Other serious complication 42 (3.9%) 1 (0.3%) 2 (0.9%) 39 (7.0%) o0.0001
Day first complication appeared, median (range) 3 (0–15) 13 (5–15) 7 (0–15) 3 (0–15) 0.020
Cause of death at 15 days
PE 19 (1.8%) 0 2 (0.9%) 17 (3.1%) 0.001
Mixed cause 17 (1.6%) 0 0 17 (3.1%) o0.0001
Bleeding 6 (0.6%) 0 1 (0.5%) 5 (0.9%) 0.088
Disease progression 45 (4.2%) 1 (0.3%) 10 (4.7%) 34 (6.1%) o0.0001
Sepsis 8 (0.7%) 0 0 8 (1.4%) 0.012
Arterial thrombosis 0 0 0 0 —
Other reason 14 (1.3%) 0 0 14 (2.5%) 0.001
Venous rethrombosis within 15 days 8 (0.7%) 3 (1.0%) 0 5 (0.9%) 0.959
Recurrence of PE at 15 days 43 (4.0%) 16 (5.2%) 13 (6.1%) 14 (2.5%) 0.030
Arterial rethrombosis within 15 days 25 (2.3%) 2 (0.7%) 8 (3.8%) 15 (2.7%) 0.095
30-day mortality 153 (14.2%) 4 (1.3%) 19 (8.9%) 130 (23.3%) o0.0001
Abbreviations: ICU¼ intensive care unit; PE¼pulmonary embolism. Percentages refer to columns. It was possible to record more than one serious complication for the same patient; causes of
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Figure 3. Cumulative hazard functions for serious complications. In this
figure, cumulative hazard curves were plotted to show the change in
hazards over time (days), for each prognostic category.
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and are better suited to elaborating decision-making algorithms
that follow the same structure (Yohannes and Hoddinott, 1999;
Lewis, 2000). Thus, in the real world, decisions in subjects with PE
are not generally made on the basis of the small additive
contributions of several variables, but on the presence or absence
of strong dichotomous predictors such as cardiogenic shock, acute
respiratory failure, hypotension, etc. (Wicki et al, 2000; Aujesky
et al, 2006; Uresandi et al, 2007; Jiménez et al, 2010; Kline et al,
2012; Den Exter et al, 2013). The presence of a single one of these
variables indicates high risk and is fundamental in the clinical
decision to intensify therapy, regardless of the contribution of the
remaining covariates of a logistic regression model. Decision trees
are also useful in situations having non-linear probable effects for
some variables, as is assumed in a sample of patients diagnosed
using different methods (CT-angiography scans vs conventional
CT) and having dissimilar clinical characteristics, depending on if
they are incidental or symptomatic events. Insofar as the previously
developed scales are concerned (RIETE, POMPE-C, PESI, etc.)
(Aujesky et al, 2006; Jiménez et al, 2010; Kline et al, 2012; Den
Exter et al, 2013), we do not know for sure if they can complement
these criteria, although a preliminary analysis performed by our
group suggests that their use is not likely to be necessary after
applying a clinical classification rule (Carmona-Bayonas et al,
2016).
Another striking difference between the EPIPHANY index and
the afore-mentioned methods is that we propose beginning to use
the probability of serious complications within 15 days as the
primary end point and not all-cause 30-day mortality, which had
been typically used in other studies (Aujesky et al, 2006; Jiménez
et al, 2010; Kline et al, 2012; Den Exter et al, 2013). Of course we
agree that mortality is a far more solid outcome; nonetheless, we
believe that considering other end points in different clinical
situations, as our group recently proposed (Carmona-Bayonas
et al, 2016), is justified. One of the arguments is that the
appearance of serious complications in individuals with PE treated
as outpatients, far from medical supervision, can paradoxically
turn low-risk patients into the most vulnerable, because of
misclassification. In contrast, the probability of all-cause 30-day
mortality will not necessarily affect decision-making regarding
ambulatory treatment in some subgroups, as the cause of death is
rarely the PE itself, and is often due to cancer progression (Den
Exter et al, 2013; Carmona-Bayonas et al, 2016). In fact, patients on
palliative care for advanced disease are those in whom it is even
more important to prevent unnecessary hospitalisation at the end
of their lives. The use of the all-cause 30-day mortality end point
also entails the issue of proposing intensification of PE
management (e.g., with fibrinolysis) in subjects at greater risk of
early mortality due to cancer, who are precisely the ones
who are less likely to benefit. For instance, when we examine the
causes of death 15, 30, and 90 days after PE, cancer is the cause of
death in 35%, 54%, and 65%, respectively. Although determining
the cause of death in absence of autopsies has clear limitations, the
same data appear in the RIETE registry, in which B50% of the
deaths resulted from the cancer itself and not PE (Den Exter et al,
2013).
This study has certain limitations that must be taken into
account. First of all, it is a fundamentally retrospective registry of
medical history data, with the intrinsic limitations in precision this
entails. Nevertheless, most of the events contemplated are solid and
are faithfully recorded in the histories (blood pressure, oxygen
saturation, documentation of tumour response, ECOG-PS, exitus,
etc.). Second, PE is a highly polymorphic pathology and more
external validations are needed by other groups, being cognizant
that these models offer a general overview of the main risk factors.
However, some subjects have other particular factors with a
definitive impact on prognosis. Third, decision tree modelling can
be weak, unstable predictors in certain contexts. Thus, random
forest models that incorporate the prediction of multiple,
individual decision trees may perform better, albeit they are also
more complicated to interpret and use in daily practice (Breiman,
2001). It is also doubtful that they can achieve a better definition of
‘low risk’. Finally, the assimilation and integration of radiological
variables and/or biomarkers (e.g., troponin, pulmonary artery
obstruction indices, right ventricular dilatation, etc.) would call for
more in-depth studies.
In short, we have elaborated a decision tree to predict serious
complications in cancer patients with PE that enables patients to be
classified into groups of high, intermediate, and low risk for
complications. This model validates and refines the classification
rules previously used by other authors; it is based on variables that
are easy to obtain; it’s easy to use, and can have potential
implications for clinical management.
ACKNOWLEDGEMENTS
We thank Priscilla Chase Duran for editing the text. This project
was funded in part by a restricted educational grant from Leo
Pharma Spain and by support from the Asociación de Investiga-
ción de la Enfermedad Tromboembólica de la Región de Murcia
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